Using dicarboxylic acid therapy to prevent kidney injury
Dicarboxylic acid therapy for prevention of kidney injury
This study is looking at a new treatment using dicarboxylic acid to help protect your kidneys from damage during serious health events, with the hope of improving recovery and preventing long-term kidney problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10878038 on NIH RePORTER |
What this research studies
This research investigates the use of dicarboxylic acid therapy as a potential treatment to prevent acute kidney injury (AKI), which is a serious condition often occurring in hospital settings. The study aims to explore how this therapy can protect kidney cells from damage and reduce the risk of progression to chronic kidney disease (CKD) after an acute event. By focusing on metabolic signaling and the role of peroxisomal fatty acid oxidation, the research seeks to develop a novel intervention that could improve kidney health outcomes. Patients participating in this research may receive new treatment options that could enhance their recovery and long-term kidney function.
Who could benefit from this research
Good fit: Ideal candidates for this research are hospitalized patients who are at risk of developing acute kidney injury, particularly those with underlying health conditions that may exacerbate kidney damage.
Not a fit: Patients who have pre-existing end-stage renal disease or those not currently hospitalized may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic approach to prevent kidney injury and reduce the risk of chronic kidney disease in at-risk patients.
How similar studies have performed: While there has been significant research on kidney injury prevention, the specific approach of using dicarboxylic acid therapy is novel and has not been extensively tested in clinical settings.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Sims-Lucas, Sunder — University of Pittsburgh at Pittsburgh
- Study coordinator: Sims-Lucas, Sunder
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.